In summary, we have shown that HD-derived anti-BCMA CAR T cells have a distinct immune phenotype and superior long-term in vitro activity compared with relapsed multiple myeloma–derived CAR T cells. This evidence concerns the gene TNFRSF17 and AL amyloidosis.